or
Bookmark and Share
Calcium channel blockers comprising two benzhydril moieties
   
Document Number
US Patent 6951862
Issued Date
October 4, 2005
Link
Map
Abstract
Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
38
Comments:
no comments yet
Owner
Published
October 4, 2005
Application Number
10/409,763
Filed
April 8, 2003
US Classification
514/255.01   544/381 544/391
Int'l Classification
A61K   31/496   (20060101)   A61K   31/451   (20060101)   A61K   31/4515   (20060101)   A61K   31/454   (20060101)   A61K   31/4545   (20060101)   A61K   31/498   (20060101)   A61K   31/5415   (20060101)   C07D   295/185   (20060101)   C07D   211/00   (20060101)   C07D   211/14   (20060101)   C07D   211/58   (20060101)   C07D   211/46   (20060101)   C07D   295/00   (20060101)   C07D   401/00   (20060101)   C07D   295/03   (20060101)   C07D   401/04   (20060101)   A61K   31/5375   (20060101)   A61K   31/4523   (20060101)   A61K   31/495   (20060101)   A61K   31/506   (20060101)   A61K   31/4468   (20060101)   A61K   31/538   (20060101)   C07D   211/16   (20060101)   C07D   317/60   (20060101)   C07D   213/00   (20060101)   C07D   213/38   (20060101)   C07D   317/00   (20060101)   C07D   277/82   (20060101)   C07D   277/74   (20060101)   C07D   277/00   (20060101)   C07D   401/14   (20060101)  
Attorney/Law Firm
Parent Case
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of U.S. Ser. No. 10/060,900 filed Jan. 29, 2002 now U.S. Pat. No. 6,617,322, which is a continuation of U.S. Ser. No. 09/476,927 filed 30 Dec. 1999, now U.S. Pat. No. 6,387,897; which is a continuation-in-part of U.S. Ser. No. 09/401,699, filed 23 Sep. 1999, now U.S. Pat. No. 6,294,533; which is a continuation-in-part of U.S. Ser. No. 09/107,037 filed 30 Jun. 1998, now U.S. Pat. No. 6,011,035. The contents of these applications are incorporated herein by reference.
USPTO Field of Search
514/255.01   544/391   544/381  
Related Patents
7378420 - Urea derivatives as calcium channel blockers - Owned by Neuromed Pharmaceuticals Ltd. (Vancouver, British Columbia,CA)

Derivatives of urea that contain piperazine rings and additional substitution with aromatic groups are effective in ameliorating conditions associated with unwanted calcium ion channel activity.

7186726 - Preferentially substituted calcium channel blockers - Owned by Neuromed Pharmaceuticals Ltd. (Vancouver,CA)

Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

7511077 - Diamine calcium channel blockers - Owned by Neuromed Pharmaceuticals Ltd. (Vancouver,CA)

Aromatic derivatives of aliphatic diamines are effective in ameliorating conditions characterized by unwanted calcium ion channel activity, especially T-type and N-type channels. These conditions include, for example, stroke and pain.

7407957 - Phthalazinone derivatives - Owned by Maybridge Limited (Cornwall,GB) Kudos Pharmaceuticals Limited (Cambridge,GB)

A compound of formula (I): ##STR00001## for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NR.sup.X or CR.sup.XR.sup.Y; if X=NR.sup.X then n is 1 or 2 and if X=CR.sup.XR.sup.Y then n is 1; R.sup.X is selected from the group consisting of H, optionally substituted C.sub.1-20 alkyl, C.sub.5-20 aryl, C.sub.3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R.sup.Y is selected from H, hydroxy, amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1 and R.sup.C2 are independently selected from the group consisting of hydrogen and C.sub.1-4 alkyl, or when X is CR.sup.XR.sup.Y, R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R.sup.1 is selected from H and halo; and Het is selected from: ##STR00002## where Y.sup.1 is selected from CH and N, Y.sup.2 is selected from CH and N, Y.sup.3 is selected from CH, CF and N, where only one or two of Y.sup.1, Y.sup.2 and Y.sup.3 can be N; and ##STR00003## where Q is O or S.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us